CSG’s Twin Supply?Chain Plays: A Fuze Factory and a Chemical Stake

Czechoslovak Group invests in electronic fuzes via JV with Reunert and boosts stake in Alzchem for nitroguanidine, aiming to fortify ammo production amid record orders.

The Czechoslovak Group is shoring up two of the most vulnerable points in ammunition production—electronic ignition systems and chemical precursors—through separate, parallel moves that underline its push for backward integration. In Slovakia, the company has teamed up with South Africa’s Reunert to build a joint venture dedicated to electronic fuzes for large?calibre munitions, while simultaneously expanding its economic exposure to German speciality chemicals group Alzchem, a producer of nitroguanidine used in propellants and munitions.

The fuze venture, to be named Fuchs Electronics Europe, will be split 51?49 in favour of Reunert, with CSG contributing its existing infrastructure at ZVS Dubnica nad Váhom. Technology will come from Fuchs Electronics Proprietary Limited, a supplier with export contracts across Europe, the Middle East, India and Southeast Asia. Crucially, the new unit is designed to operate independently of any single munitions maker or customer, giving it flexibility in a market where electronic fuzes remain a scarce resource within the EU.

CSG has already secured two order packages—both in the high double?digit millions—for mechanical and electronic fuzes from European NATO customers. Deliveries are scheduled to start this year, with Fuchs Electronics Europe plugging into the electronic fuze portion. A binding launch order is expected to cover the ramp?up period, and management sees the unit becoming self?sustaining after roughly three years, delivering margins that should add value for both partners.

On the chemicals front, CSG’s trading arm STALUNA TRADE a.s. now holds 9.9% of Alzchem’s voting rights directly, with a further 10.2% exposure via total return swaps that run to May 2027. The combined reported position of approximately 20.1% gives CSG meaningful economic influence without immediately expanding voting control. Alzchem has said CSG confirmed its role as a long?term oriented investor and that no changes to strategy or management are planned. The stake builds on an earlier 9.2% holding and fits CSG’s ambition to strengthen its footprint in Germany, particularly in chemicals linked to defence.

The operational picture remains robust. In the opening quarter, CSG posted a 13.8% revenue gain to €1.54 billion, while the order backlog hit a record €17 billion. A further €27 billion worth of projects are under negotiation. Full?year revenue guidance is unchanged at €7.4–€7.6 billion, with an adjusted EBIT margin of 24–25%—a level that would keep the company among the most profitable in the European defence industry.

Yet the stock continues to trade well below its January IPO price of €25. At Wednesday’s close of €15.60, the shares have fallen 13.68% over the past week and sit 22.65% below their 50?day moving average. The relative strength index at 34.0 points to persistent selling pressure, although analysts remain uniformly bullish: the consensus price target stands at €32.45, with ten buy ratings and no sells.

The fuze venture still requires regulatory approval, including clearance for foreign investments and defence?related export controls. Because electronic fuzes are sensitive items in NATO supply chains, the involvement of a South African technology partner—even in a minority role—may invite extra scrutiny. No timeline has been given for the necessary permits, but once secured, the new production line could be feeding European artillery rounds before the year is out.